Russian biotech developer reports good clinical trial results for its HIV drug
Viriom, a Moscow-based biotech developer, has announced positive results of the latest international clinical trial testing of its innovation drug to fight the HIV
Viriom, a Moscow-based biotech developer, has announced positive results of the latest international clinical trial testing of its innovation drug to fight the HIV, Rusnanonet.ru reported. During the testing, its VM-1500 drug candidate is said to have demonstrated ?unique pharmacokinetic properties and, unlike other drug candidates in this pharma class, strong resistance to the HIV,? the source quoted a company spokesman as saying. According to Dr. Vadim Bychko, the scientific director of Viriom, this round of clinical trials was conducted in Russia and Thailand and has revealed that the VM-1500 is ?safe, produces no negative effect on healthy volunteers and chronic HIV-1 patients alike after both one-time and multiple peroral administering of the substance, and also shows favorable pharmacokinetics.? The results that have been obtained in the two countries give Viriom grounds to believe that the VM-1500 ?has the potential to become the best in its class,? Dr...
Viriom, a Moscow-based biotech developer, has announced positive results of the latest international clinical trial testing of its innovation drug to fight the HIV, Rusnanonet.ru reported. During the testing, its VM-1500 drug candidate is said to have demonstrated ?unique pharmacokinetic properties and, unlike other drug candidates in this pharma class, strong resistance to the HIV,? the source quoted a company spokesman as saying. According to Dr. Vadim Bychko, the scientific director of Viriom, this round of clinical trials was conducted in Russia and Thailand and has revealed that the VM-1500 is ?safe, produces no negative effect on healthy volunteers and chronic HIV-1 patients alike after both one-time and multiple peroral administering of the substance, and also shows favorable pharmacokinetics.? The results that have been obtained in the two countries give Viriom grounds to believe that the VM-1500 ?has the potential to become the best in its class,? Dr...
Похожее
Russian developer pushes brand new tuberculosis drug
NeuroMax steps up testing of its drug for diabetes complications
New C-type hepatitis drug safe, no side effect, developer claims
Russian start-up takes its cancer drug candidate to US for clinical trials
Yaroslavl biotech innovators develop new chronic C-type hepatitis drug
A design company of RVC tested its drug against atherosclerosis